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tatins in Aortic Stenosis
ew Data From a
rospective Clinical Trial*
rian P. Griffin, MD, FACC
leveland, Ohio
egenerative aortic stenosis is the valve lesion in which our
nderstanding of pathophysiology is most advanced. De-
enerative changes in the aortic valve increase with age but
o not inexorably lead to stenosis (1). Degenerative aortic
tenosis has many similarities to atherosclerotic plaque
istologically, and has many similar predisposing risk factors
2,3). Genetic factors also play a role, and specific isoforms
f both apolipoproteins and vitamin D receptors increase
he likelihood of disease (4,5). In experimental animal
odels, very-high-cholesterol diets produce degenerative
hanges in the aortic valve similar to those seen in humans.
See page 554
n these models, oxidized low-density lipoprotein (LDL)
holesterol induces the production of calcium-binding pro-
eins and the transformation of valve cells into chondro-
lasts and osteoblasts that may lead to cartilage and bone
ormation, findings recorded in human aortic valves in
ate-stage untreated stenosis (6–8). Valve tissue is normally
elatively avascular. However, with inflammation angiogen-
sis occurs, especially at the site of tissue damage. It has
een reported recently that a protein chondromodulin-1 is
n antiangiogenesis factor in normal valves and is present in
ignificantly reduced amounts at the site of tissue damage,
uch as the site of degenerative change, especially in aortic
alves (9). Clearly, therefore, the aortic valve is a complex
tructure with many separate processes that may modulate
isease.
Statin therapy has been proposed as a way to slow the rate
f progression of aortic stenosis given the similarity with
therosclerosis. Retrospective studies have indicated a ben-
fit of statins in reducing the rate of progression of aortic
tenosis (10–14). In all of these studies, patients received
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiovascular Disease Training Program, Cleveland Clinic, Cleveland,t
hio. Dr. Griffin is an investigator of a trial of atorvastatin in aortic stenosis that has
een partly funded by Pfizer.tatins based on their physician’s preference, and those
eceiving statins had greater concentrations of standard risk
actors for atheroma and aortic valve degeneration such as
yperlipidemia, coronary artery disease, and diabetes. Statin
herapy slowed the rate of progression as compared with the
ate in those patients not receiving statins. Most of the
atients in these studies had mild or moderate aortic
tenosis, but in one study a beneficial effect of statin therapy
as seen even in those with severely narrowed valves (14). In
ach of these studies, the effect of statin therapy in reducing
he progression of aortic stenosis bore little relationship to
he quantitative reduction in LDL cholesterol.
There are now 2 prospective studies of statin treatment
eported, one of which is published in this issue of the
ournal (15,16). Prospective studies in this area are difficult
ecause many of the subjects with degenerative aortic
tenosis have comorbid conditions that mandate statin
herapy. These include coronary artery disease, diabetes, and
evere hyperlipidemia. Both prospective studies have man-
ged this problem differently. Not surprisingly, therefore,
heir findings and conclusions are also different. In the
ALTIRE (Scottish Aortic Stenosis and Lipid Lowering
rial, Impact on Regression) study performed in Scotland,
55 patients, 70% of whom were men and whose mean age
as 68 years, were prospectively randomized to atorvastatin
0 mg or placebo and were followed up for 2 years with
chocardiograms performed at yearly intervals (15). Only
hose patients in whom statins were not indicated for other
easons were included in the study. Thus, the patients
ncluded in the study had an LDL cholesterol average of
34 mg/dl and there were relatively few patients with
iabetes, although a significant minority had coronary or
ther vascular disease. The average valve area at inception in
he study was 1 cm2, and the calcification of the valves as
ssessed by computed tomographic (CT) scanning was
xtensive. Statin therapy had no effect on the rate of
rogression of aortic stenosis over the 2 years of follow-up as
ssessed by Doppler echocardiography or by change in CT
alcium score of the valve, despite reducing the LDL
holesterol by more than 50%. The average reduction in
ortic valve area in the treatment and control arm was 0.08
m2 per year, which is similar to that recorded in natural
istory studies of aortic stenosis, in which an average rate of
rogression of 0.1 cm2 per year has been reported. In
respecified analyses, the effect of treatment was evaluated
n subgroups of severity of aortic stenosis based on a peak
ortic jet velocity at baseline of 4 m/s and also based on
ength of follow-up. Although those with more severe
tenosis progressed significantly more rapidly than those
ith less severe stenosis, statins did not affect progression
ate in either group. Similarly statin therapy was ineffective
n slowing progression regardless of duration of follow-up.
econdary end points such as death, need for aortic valve
eplacement, or hospitalization were somewhat higher in
he control group but were not statistically different.
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February 6, 2007:562–4 Editorial CommentIn the second prospective study of statins in degenerative
ortic stenosis, by Moura et al. (16), those patients with
egenerative aortic stenosis for whom statin therapy is
ndicated because of hyperlipidemia are used as the active
reatment arm, although any patient with known coronary
isease was excluded from the study. These patients were
iven rosuvastatin 20 mg. The control arm of the study
onsisted of patients with degenerative aortic stenosis in
hom statin therapy was not mandated by treatment
uidelines. Thus, although prospective, this current study
as not randomized. The average age of the 121 patients
as 74 years, and 47% were men. Only those with an aortic
alve area of 1 cm2 were included, and the average valve
rea in both the control and the treatment arms was 1.2
m2. However, the statin group had by design LDL levels of
130 mg/dl (on average 160 mg/dl), whereas those receiv-
ng no statin treatment had an LDL 130 mg/dl (average
evel 118 mg/dl). There were other significant differences
etween the treatment groups. Only 34% of those given statins
ere men, as compared with 60% in the nontreatment arm,
nd those receiving statins were more likely to be hypertensive
nd diabetic and had higher triglyceride levels than those in the
ntreated group. The annualized reduction of the valve area in
hose receiving statins was 0.05 cm2 per year, versus 0.1 cm2 in
hose not receiving statins. The LDL cholesterol level did not
hange significantly over the 18 months of follow-up in the
ontreatment arm, whereas it decreased more than 40% in the
tatin arm. The rate of progression of stenosis was modestly
nversely correlated with the change in LDL level over the
uration of follow-up.
So how do we resolve the differences in the findings of the
wo prospective trials of statin therapy in degenerative aortic
tenosis and integrate them with the extensive experimental
nd retrospective studies that suggest that statin therapy
ay slow the rate of progression of degenerative aortic
tenosis? From a clinical viewpoint, those patients with
omorbid conditions such as coronary artery disease or
iabetes or who are significantly hyperlipidemic will be
reated with statins anyway. The wealth of evidence, includ-
ng the present study, suggests that such patients will also
njoy a beneficial effect in terms of slowing the progression
f aortic stenosis in addition to reduction in other cardio-
ascular end points. The target LDL in this group of
atients needed to maximize the effects on aortic valve
rogression is unknown. Given the modest correlation
etween beneficial valve effect and LDL reduction, the
arget LDL required for treatment of the primary disease for
hich statins are being prescribed will likely be adequate, at
east until more evidence is available. Similarly, there is no
vidence yet of a unique advantage in terms of beneficial
ffects on the aortic valve of any specific statin.
What of those patients with degenerative aortic stenosis
n which current lipid treatment guidelines do not mandate
tatin therapy? Will these patients benefit from statin
herapy? Unfortunately, the study by Moura et al. (16) does
ot help us that much in this regard, because many of theatients in the active treatment arm would likely meet
uidelines for statin therapy anyway based on their risk
actors. In the SALTIRE study, such patients did not seem
o benefit from statin therapy, at least over 2 years of
ollow-up. However, the SALTIRE study is a relatively
mall one and the patients had relatively advanced aortic
tenosis not just in terms of valve area, but also in terms of
he calcification of the valve at the onset of the trial, and
ay therefore have been less amenable to a treatment effect
f statins. It is also possible that in patients without severe
yperlipidemia, progression of aortic valve disease is mod-
lated by factors other than lipid metabolism. Until further
ata are available, there does not seem to be an indication
or statin therapy just on the basis of aortic stenosis alone if
onventional guidelines for statin therapy are not met.
ortunately, other trials are currently in process that may
elp address not just whether statins affect progression of
ortic valve disease but also whether they affect more
ignificant end points such as mortality or the need for
ortic valve surgery. The SEAS (Simvastatin and Ezetimibe
n Aortic Stenosis) trial in process is randomizing 1,800
atients with asymptomatic aortic stenosis to simvastatin 40
g and ezetimibe 10 mg daily or placebo to determine the
ffect of active treatment on such end points. Given that
ven those patients with aortic sclerosis have a significantly
igher risk for cardiovascular events, the results should be
nteresting indeed (17).
eprint requests and correspondence: Dr. Brian P. Griffin,
ardiovascular Disease Training Program, Cleveland Clinic, 9500
uclid Avenue, Cleveland, Ohio 44195. E-mail: griffib@ccf.org.
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